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Glucocorticoids (GCs) are the cornerstone of the therapy in many autoimmune and inflammatory diseases. However, it is well
known that their use is a double edged sword, as their beneficial effects are associated almost universally with unwanted effects, as,
for example glucocorticoid-induced osteoporosis (GIO). Over the last years, several clinical practice guidelines emphasize the need
of preventing bonemass loss and reduce the incidence of fractures associatedwithGCuse. Calciumand vitaminD supplementation,
as adjunctive therapy, are included in all the practice guidelines. However, no standard vitamin D dose has been established.
Several studies with postmenopausal women show that maintaining the levels above 30–33 ng/mL help improve the response to
bisphosphonates. It is unknown if the response is the same in GIO, but in the clinical practice the levels are maintained at around
the same values. In this study we demonstrate that patients with autoimmune diseases, undergoing glucocorticoid therapy, often
present suboptimal 25(OH)D levels. Patients with higher bodymass index and those receiving higher doses of glucocorticoids are at
increased risk of having lower levels of 25(OH)D. In these patients, calcidiol supplementations aremore effective than cholecalciferol
to reach adequate 25(OH)D levels.
1. Introduction
Glucocorticoids (GCs) are the cornerstone of the therapy in
many autoimmune and inflammatory diseases [1]. However,
it is well-known that their use is a double edged sword, as
their beneficial effects are associated almost universally with
unwanted effects, as, for example, glucocorticoid-induced
osteoporosis (GIO), the most widespread type of secondary
osteoporosis [2]. Over the last years, several clinical practice
guidelines emphasize the need of preventing bone mass
loss and reduce the incidence of fractures associated with
GC use [3, 4]. Calcium and vitamin D supplementation, as
adjunctive therapy, are included in all the practice guidelines,
as calcium and vitamin D supplements have been routinely
administered in most clinical trials. However, no standard
vitamin D dose has been established. One option is to
administer a fixed dose ranging between 800 and 1000 IU/day
[3], although the best way to achieve the appropriate supply
may be the assessment of plasma 25(OH)D levels [4]. Several
studies with postmenopausal women show that maintaining
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the levels above 30–33 ng/mL helps improving the response
to bisphosphonates [5–7]. However, it is unknown if the
response is the same inGIO [8], but in the clinical practice the
levels are maintained at around the same values. In subjects
with normal renal function, cholecalciferol, ergocalciferol,
or calcidiol can be used to correct vitamin D deficiency.
Although calcidiol can be consideredmore rapid and effective
in subjects with vitamin D deficiency [9, 10] to the best of
our knowledge, there are no available data on its benefit in
patients with GIO.
Taking into account these considerations, we aimed at
assessing the factors associated with suboptimal 25(OH)D
levels and analyzing if oral calcidiol is more effective than
cholecalciferol supplementation to reach adequate 25(OH)D
levels in patients with autoimmune diseases chronically
treated with low doses of glucocorticoids.
2. Methods
2.1. Study Design and Patients. This was a real-life study
in which patients with autoimmune diseases, undergoing
GC therapy, followed up at the Outpatient Clinic of the
Systemic Autoimmune Diseases Unit at San Cecilio Hospital
in Granada (Spain) (a university teaching hospital), between
January 2010 and September 2013 were assessed. The study
was approved by the Clinical Research Ethics Committee of
the San Cecilio Hospital. All participants gave their written
consent in accordance with the Declaration of Helsinki.
2.2. Inclusion Criteria. The inclusion criteria included
patients 18 years old and older who have been on GC therapy,
for more than three months before the date of recruitment,
and who were expected to continue receiving glucocorticoids
in a stable dose, because of the underlying autoimmune
disease, for at least another three months, and in whom their
doctor had indicated the use of calcidiol or cholecalciferol
for the prevention of GIO.
2.3. Exclusion Criteria. The exclusion criteria included
patients who had been treated with 6-methylprednisolone
pulses or who required higher doses of prednisone 15mg/d
for disease control, and those suffering from other dis-
eases such as neoplasia, liver disease, hyperparathyroidism,
hypercalcemia, hypercalciuria, hypophosphatemia, or renal
insufficiency (creatinine levels >1.5mg/dL) were excluded.
2.4. Procedure. At the time of inclusion relevant clinical data
including the dose of GC and the drugs used to avoid the
potential bone mass loss mediated by GC, including type
of vitamin D supplement (cholecalciferol or calcidiol), was
assessed. At each visit, clinical data related to the patient’s dis-
ease, as well as his/her adherence to the indicated treatment,
were recorded.The interval between two visits was not longer
than 6 months with a follow-up of one year. The average
prednisone dose was calculated by dividing the accumulated
prednisone dose between the days of follow-up. Laboratory
determinations in fasting conditions were done at inclusion.
During follow-up, 25(OH)D levels were also measured. At
least two determinations were obtained for each patient, one
during spring-summer (from April 1 to September 30) and
another during fall-winter (from October 1 to March 31).
We established the mean 25(OH)D level for each patient
considering the values obtained in both periods. Regarding
vitamin D, values ≥30 ng/mL were considered optimal and
values<30 ng/mLwere considered suboptimal (insufficient at
concentrations between 15 ng/mL and 30 ng/mL anddeficient
at concentration <15 ng/mL).
During the study visits, patients were asked for any
adverse events. Serum calcium levels and urinary calcium
excretion (calcium/creatinine ratio in spot urine) were
assessed at each visit.
2.5. Measurements of 25(OH)D. 25(OH)D assessment was
done using the IDS-iSYS25OHD kit supplied by Immun-
odiagnostic Systems Ltd (Boldon, England), a chemilumi-
nescence direct competitive immunoassay for quantitative
determination of total serum or plasma25(OH)D. The intra-
and interassay coefficient of variations (VC%) were below
12.1% and 16.9%, respectively.
3. Statistical Analysis
For the analysis of the data the Kolmogorov-Smirnoff test
was applied to establish the goodness of fit to normality
for the variables studied. Descriptive statistics (mean ± SD)
were determined for all variables. Student’s 𝑡-test was used
to compare quantitative variables. Categorical variables and
proportions were analysed using the Chi-square test. Inter-
group comparison of 25(OH)D concentrationswas donewith
one-way ANOVA. Correlation analyses were performed with
Pearson’s or Spearman’s rank order correlation coefficients,
where appropriate. Finally, a logistic regression analysis was
performed to assess the factors that could independently
influence the presence of suboptimal levels of 25(OH)D.
The strength of the association was expressed by odds ratio
(OR) with confidence interval of 95%. In all analyses, 𝑝
value <0.05 was interpreted as statistically significant. All
statistical analyses were performed using SPSS version 17.0
(IBM, Armonk, NY, USA).
4. Results
One hundred forty-seven subjects (all Caucasian) were
included in the analysis (67 lupus erythematosus; 35 systemic
vasculitis; 11 rheumatoid arthritis; 10 sarcoidosis; 9 inflam-
matory myopathies; 15 others). All the patients were from
Granada, a sunny Andalucian city (37∘ 11󸀠󸀠 north latitude)
with 3016 hours of sun per year. Eighty-six patients received
cholecalciferol (800 IU/day) plus 3000mg/day of calcium
carbonate, in twodoses, and 49 patients calcidiol (10.640 IU/4
weeks [equivalent 354 IU/d]). At the time of inclusion in the
study, the patients were already on calcidiol or cholecalciferol
for at least three months. Patients treated with calcidiol were
instructed to make a diet with at least 1200mg/d of calcium.
Twelve patients, who were prescribed treatment, received
no supplements by patient personal choice, fearing possible
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Table 1: Baseline characteristics of the subjects included in the
study.
𝑁 Mean SD %







Weight (kg) 147 72 16
Height (cm) 147 160 9










(vitamin D3) 86 58.5%
Calcidiol (25[OH]D3) 49 33.3%
Table 2: Baseline characteristics of the cholecalciferol and calcidiol
groups.
Cholecalciferol Calcidiol 𝑝
Age (mean ± SD) 56.6 ± 14.5 57.4 ± 19.0 NS
Gender (𝑁, %)
Men 21 (24.4) 6 (12.2) NS
Female 65 (75.6) 43 (87.8)
Menopause (𝑁, %) 44 (67.7) 20 (46.5) 0.028
BMI (mean ± SD) 28.9 ± 5.84 26.40 ± 4.53 0.010
Prednisone, mg/day
(mean ± SD) 5.2 ± 2.74 4.0 ± 2.59 NS
adverse effects. The mean prednisone or equivalent dose was
5.24±2.91mg/d. Basal characteristics of the patients included
in the study are shown in Tables 1 and 2. Patients treated
with calcidiol had a lower BMI (28.9 ± 5.8 versus 26.4 ± 4.5;
𝑝 = 0.010); and women in this group were less frequently
menopausal (46.5 versus 67.7; 𝑝 = 0.028).
Assessment of the mean annual 25(OH)D levels in the
whole group of 147 patients revealed normal, insufficient, and
deficient levels in 46.9%, 40.8%, and 12.2% of the patients,
respectively. During the spring-summer period, 55.1% of
the 147 patients had 25(OH)D levels >30 ng/mL, 34.7% had
insufficient levels, and 10.2% had deficient levels. During
the fall-winter period, 42.3% of them had normal 25(OH)D
levels, 46.2% had insufficient levels, and 11.5% deficient levels.
Table 3 shows the levels of 25(OH)D in the total sample and























Figure 1: 25(OH)D levels (ng/mL) throughout the year in patients
receiving cholecalciferol or calcidiol or not taking vitamin D
(controls).
A statistically significant negative correlation between
25(OH)D levels and body mass index (BMI) (𝑟 = −0.19;
𝑝 = 0.03) or daily prednisone dose (𝑟 = −0.25; 𝑝 = 0.003)
was observed.
With regard to the season of the year and vitamin D
intake, we found that patients treated with calcidiol had
higher 25(OH)D concentration when compared with those
treated with cholecalciferol or with those who did not receive
vitamin D3 supplements; however, these differences were
only statistically significant in winter (𝑝 < 0.0001) or when
25(OH)D annual mean value was assessed (𝑝 = 0.002)
(Figure 1).
All variables of interest were tested for association with
suboptimal 25(OH)D levels. The results are presents in
Table 4. The correct classification rate of the model was 65%,
with a specificity of 55.7% and a sensitivity of 73%. Daily
prednisone dose (mg/d) was independently associated with
suboptimal 25(OH)D levels (OR = 1.83; CI 95%, 1.021–1.372;
𝑝 = 0.026) and calcidiol supplements were a protective factor
for suboptimal 25(OH)D (OR = 0.441; CI 95% 0.209–0.928;
𝑝 = 0.031).
No hypercalcemia or hypercalciuria was observed in any
patient, regardless of treatment.
5. Discussion
There is still controversy over the 25(OH)D levels that
should be considered as normal in humans. The 25(OH)D
concentration in people living like our ancestors did, such
as the Masai, and in children and adults from South Africa
and Gambia ranges between 30 and 45 ng/mL. In this
regard, some authors concluded that these ranges are the
desirable values for optimal skeletal and extraskeletal health
[11], while others consider a level above 20 ng/mL as the
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Table 3: 25(OH)D levels in different seasons of the year: (a) total; (b) cholecalciferol; (c) calcidiol.
(a)
𝑁 = 147 %
25(OH)D Optimal ≥30 ng/mL 81 55.1%
Spring-summer Suboptimal Insufficient 15–30 ng/mL 51 34.7%
Deficient <15 ng/mL 15 10.2%
25(OH)D Optimal ≥30 ng/mL 55 42.3%
Autumn-winter Suboptimal Insufficient 15–30 ng/mL 60 46.2%
Deficient <15 ng/mL 15 11.5%
25(OH)D Optimal ≥30 ng/mL 69 46.9%
Average per year Suboptimal Insufficient 15–30 ng/mL 60 40.8%
Deficient <15 ng/mL 18 12.2%
(b)
𝑁 = 86 %
25(OH)D Optimal ≥30 ng/mL 44 51.2%
Spring-summer Suboptimal Insufficient 15–30 ng/mL 34 39.5%
Deficient <15 ng/mL 8 9.3%
25(OH)D Optimal ≥30 ng/mL 26 35.6%
Autumn-winter Suboptimal Insufficient 15–30 ng/mL 36 49.3%
Deficient <15 ng/mL 11 15.1%
25(OH)D Optimal ≥30 ng/mL 36 41.9%
Average per year Suboptimal Insufficient 15–30 ng/mL 35 40.7%
Deficient <15 ng/mL 15 17.4%
(c)
𝑁 = 49 %
25(OH)D Optimal ≥30 ng/mL 33 67.3%
Spring-summer Suboptimal Insufficient 15–30 ng/mL 11 22.4%
Deficient <15 ng/mL 5 10.2%
25(OH)D Optimal ≥30 ng/mL 27 58.7%
Autumn-winter Suboptimal Insufficient 15–30 ng/mL 17 37.0%
Deficient <15 ng/mL 2 4.3%
25(OH)D Optimal ≥30 ng/mL 30 61.2%
Average per year Suboptimal Insufficient 15–30 ng/mL 17 34.7%
Deficient <15 ng/mL 2 4.1%
Table 4: Factors linked to suboptimal 25(OH)D levels in the univariate and multiple logistic regression model, in the average of annual
determinations.
Factor Univariate logistic regression analysis Multiple logistic regression analysis
𝑝 value OR (95% CI) 𝑝 value OR (95% CI)
Age 0.88 1.00 (0.98–1.02) NS
BMI 0.32 1.03 (0.97–1.10) NS
Prednisone dosage (mg/d) 0.011 1.230 (1.04–1.39) 0.03 1.20 (1.04–1.39)
Calcidiol versus cholecalciferol 0.027 0.439 (0.21–0.91) 0.03 0.44 (0.21–0.93)
appropriate concentration [12]. In our study we defined
>30 ng/mL as the adequate concentration for 25(OH)D.
This was based on different studies that support the claim
that this concentration is optimal to improve the response
to the treatment with bisphosphonates in postmenopausal
women with osteoporosis [5–7, 13], because some authors
believe that the beneficial extraskeletal effects mediated by
vitamin D are achieved when higher 25(OH)D concentration
is reached [14]. Thus, considering 30 ng/mL as the cutoff
concentration, the first result unveiled fromour studywas the
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high prevalence of suboptimal 25(OH)D levels, despite the
fact that most patients were taking oral vitamin supplements.
This high prevalence of vitamin insufficiency has been consis-
tently observed in different countries, in both healthy people
and individuals with different diseases [15], particularly in
those with autoimmune and inflammatory diseases [16, 17].
According to our results, a fixed supply of vitamin D is not
always sufficient to maintain 25(OH)D concentrations above
30 ng/mL.
We found a correlation between BMI and 25(OH)D
levels. In keeping with our findings, a recent meta-analysis
disclosed a significant inverse weak correlation between
serum 25(OH)D levels and BMI in population of adults [18].
The only exception was found in women living in developing
countries [18]. This finding supports the need of providing
higher vitamin D doses to subjects with high BMI.
In our study, a significant negative correlation between
25(OH)D levels and the daily dose of prednisone was found.
Although some authors have found normal 25(OH)D levels
in patients receiving GC [19, 20], a recent meta-analysis, in
which patients taking at least 400 IU/day (10𝜇g/day) of vita-
min D were excluded, disclosed suboptimal 25(OH)D levels
in subjects treated with GC [21]. This was also the case in the
National andNutrition Examination Survey (NHANES) [22].
GCs increase the catabolism of 25(OH)D but they may also
induce weight gain, which, in turns, is associated with lower
25(OH)D levels. There are many other negative effects of GC
on 25(OH)D levels. In this regard, dexamethasone increases
renal expression of vitaminD-24-hydroxylase and the expres-
sion of 24-hydroxylase mRNA [23, 24], which degrades
vitamin D metabolites such as 25(OH)D and 1,25(OH)
2
D. A
functional cooperation between the GC receptor, C/EBP𝛽,
and the vitamin D receptor (VDR), which increases 24-
hydroxylase transcription, has also been described [25]. In
addition, the administration of prednisolone in rats inhibits
the activity of vitamin D3 25-hydroxylase [26]. These effects
may help to explain the low 25(OH)D concentration found in
patients of our study that received cholecalciferol. These neg-
ative effects are good reasons to determine 25(OH)D levels
and probably the administration of higher vitamin D doses,
preferably as calcidiol, in GC treated patients to prevent the
combined negative effects on bone mediated by GC and
hypovitaminosis D [21]. Some trials have also demonstrated
an advantage of calcidiol in augmentingBMD inpatients after
kidney or heart transplantation, most probably bypassing
the inhibition of 25 hydroxylases by chronic corticosteroid
therapy [27, 28].
Although the number of GC-treated patients who did not
receive any type of vitamin D supplementation in our series
was small, it is important to highlight that three-quarters of
them had suboptimal 25(OH)D levels (75%).This prevalence
was reduced in 16.9% and 36.2% in patients treated with
cholecalciferol or calcidiol, respectively, despite the fact that
patients receiving calcidiol received an average daily dose
of vitamin D less than those who received cholecalciferol
(354 versus 800 IU/d). In the multiple logistic regression
analysis, only the daily dose of prednisone and the calcidiol
supplements help to explain suboptimal 25(OH)D levels.
These findings are in agreement with data from the general
population. Bischoff-Ferrari et al. in a randomized study
compared the efficacy of calcidiol versus cholecalciferol in the
attainment of the desired serum 25(OH)D levels in healthy
postmenopausal women with vitamin D deficiency. They
showed that serum 25(OH)D concentration was twofold
increased after just 2 weeks using a daily dose of 20 𝜇g of
calcidiol reaching 30 ng/mL and then going to 69.5 ng/mL
at the end of the intervention. Conversely, the rise in serum
25(OH)D levels determined by cholecalciferol was slow,
plateauing at 31 ng/mL after 11 weeks [29]. Cashman et al.
determined that each microgram of calcidiol was five times
more effective to raise serum 25(OH)D in older adults during
winter in comparison to cholecalciferol [30], and Jetter et al.
determined that calcidiol given daily, weekly, or as a single
bolus is about 2-3 times more potent in increasing plasma
25(OH)D concentrations than vitaminD3 in healthy females,
thus allowing to get concentrations of 30 ng/mLmore rapidly
and reliably than with vitamin D3 [10].
As shown by Stamp, the administration of a single oral
dose of calcidiol produced a more rapid and significant
increase in serum 25(OH)D concentration compared to a
single oral dose of cholecalciferol, which produced a very
slow increase of serum 25(OH)D levels because of the
intermediate hepatic 25-hydroxylation [31]. This supported
an advantage of calcifediol over cholecalciferol in correct-
ing vitamin D deficiency. Indeed, calcidiol is more soluble
in organic solvents. This property influences its intestinal
absorption, its protein transport in the blood, and the whole
body distribution. The greater affinity for protein binding
may make 25(OH)D more available for internalization in
tissues devoted to the control of mineral homeostasis such
as the kidneys and the parathyroids expressing the megalin-
cubilin system of endocytic receptors [32].
The main limitation of our study is that it was not a
clinical trial but a real-life study, and we do not have levels
of 25(OH)D before initiating vitamin D supplement. Patients
received calcidiol or cholecalciferol following medical indi-
cations and not in a random manner, which could lead to
intergroup differences. Nevertheless, it is well-known that, in
some cases, the efficacy of an interventional study is better
portrayed with real-life studies [33]. We feel that the fact
that in our study patients had been included consecutively
may contribute to displaying the actual population of patients
treated with GC.
An additional limitation of our study was that we just
conducted a dietary survey as far as calcium intake is
considered, not regarding the possible intake of vitamin D,
although it must be emphasized that the rate of vitamin D
supplementation in food in Spain is very low [34], and all of
the patients live in the same Spanish province.
In summary, despite vitamin D supplementation, there is
a high prevalence of suboptimal 25(OH)D concentration in
patients treated with low doses of GC, for the management
of different autoimmune diseases. Patients with higher BMI
and those that receive higher doses of GC are at greater
risk of having insufficient levels of 25(OH)D and require
greater surveillance. Calcidiol intake contributes to lower risk
of suboptimal 25(OH)D levels than cholecalciferol and may
constitute an affordable source of vitamin D to prevent GIO.
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effects on 25(OH)D levels, lower extremity function, blood
pressure, and markers of innate immunity,” Journal of Bone and
Mineral Research, vol. 27, no. 1, pp. 160–169, 2012.
[30] K. D. Cashman, K. M. Seamans, A. J. Lucey et al., “Relative
effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in
raisingwintertime serum25-hydroxyvitaminD in older adults,”
The American Journal of Clinical Nutrition, vol. 95, no. 6, pp.
1350–1356, 2012.
[31] T. C. B. Stamp, “Intestinal absorption of 25 hydroxycholecalcif-
erol,”The Lancet, vol. 2, no. 7873, pp. 121–123, 1974.
[32] L. Cianferotti, C. Cricelli, J. A. Kanis et al., “The clinical use
of vitamin D metabolites and their potential developments:
a position statement from the European Society for Clini-
cal and Economic Aspects of Osteoporosis and Osteoarthri-
tis (ESCEO) and the International Osteoporosis Foundation
(IOF),” Endocrine, 2015.
[33] D. Price, A. Chisholm, T. van der Molen, N. Roche, E. V.
Hillyer, and J. Bousquet, “Reassessing the evidence hierarchy in
asthma: evaluating comparative effectiveness,” Current Allergy
and Asthma Reports, vol. 11, no. 6, pp. 526–538, 2011.
[34] A. I. R. Garcia, “Recommendations on vitamin D and calcium
supplements for adults in Spain,” Revista Espanola de Salud
Publica, vol. 86, no. 5, pp. 461–482, 2012.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
